This document is a published patent application from the USPTO detailing a novel capsule inhaler system for delivering phosphodiesterase-4 inhibitors. The application, assigned to Chiesi Farmaceutici S.P.A., describes a drug product that includes a single-dose dry powder inhalation device loaded with a pharmaceutical composition containing micronized particles of a specific compound and a carrier, intended for the treatment of respiratory diseases.

While patent applications are not direct regulations, they signal innovation and potential future product development in the pharmaceutical and medical device sectors. Companies involved in respiratory drug delivery, inhaler technology, or the development of phosphodiesterase-4 inhibitors should be aware of this filing as it may impact their intellectual property landscape and competitive strategies. Compliance officers in these sectors should monitor patent filings for potential licensing opportunities or competitive intelligence.